Signal transduction by protein tyrosine kinases and antitumor agents

( views:, downloads: )
MAO Yong-jun()
LI Hai-hong()
LI Jian-feng()
SHEN Jing-shan()
Journal Title:
Volume 43, Issue 04, 2008
Key Word:


  • [1]Tang ZY.Modern Oncology (现代肿瘤学)[M].2nd ed.Shanghai:Fudan University Press,2003:202-223.
  • [2]Huang WL,Zhu XF.Signal Transduction (信号转导)[M].Beijing:People's Medical Publishing House,2005:151-199.
  • [3]Sebolt-Leopold JS,English JM.Mechanisms of drug inhibition of signalling molecules[J].Nature,2006,441:457-462.
  • [4]Zhu XF,Liu ZC,Zeng YX.Tyrosine kinase receptormediated signal transduction and cancer treatment[J].Acta Pharm Sin (药学学报),2002,37:229-234.
  • [5]Deng XQ,Xiang ML,Jia R,et al.Progress in the design of selective ATP-competitive kinase inhibitors[J].Acta Pharm Sin (药学学报),2007,42:1232-1236.
  • [6]Liebmann C.Regulation of MAP kinase activity by peptide receptor signalling pathway:paradigms of multiplicity[J].Cell Signal,2001,13:777-785.
  • [7]Shaw RJ,Cantley LC.Ras,PI (3)K and mTOR signaling controls tumour cell growth[J].Nature,2006,441:424-430.
  • [8]Summy JM,Gallick GE.Treatment for advanced tumors:SRC reclaims center stage[J].Clin Cancer Res,2006,12:1398-1401.
  • [9]Schenone S,Manetti F,Botta M.Src inhibitors and angiogenesis[J].Curr Pharm Design,2007,13:2118-2128.
  • [10]Weisberg E,Manley PW,Cowan-Jacob SW,et al.Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukemia[J].Nat Rev Cancer,2007,7:345-356.
  • [11]Murray PJ.The JAK-STAT signaling pathway:input and output integration[J].J Immunol,2007,178:2623 -2629.
  • [12]Pharmaprojects V5[DB/OL].
  • [13]Kamath S,Buolamwini JK.Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development[J].Med Res Rev,2006,26:569-594.
  • [14]Scahriti M,Baselga J.The epidermal growth factor receptor pathway:a model for targeted therapy[J].Clin Cancer Res,2006,12:5268-5272.
  • [15]Ciardiello F,Bianeo R,Caputo R,et al.Antitumor activity of ZD6474,a vascular endothelial growth factor receptor tyrosine kinase inhibitor,in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy[J].Clin Cancer Res,2004,10:784 -793.
  • [16]Wedge SR,Kendrew J,Hennequin LF,et al.AZD2171:a highly potent,orally bioavailable,vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer[J].Cancer Res,2005,65:4389-4400.
  • [17]Reid A,Vidal L,Shaw H,et al.Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)[J].Eur J Cancer,2007,43:481-489.
  • [18]Naumova E,Ubezio P,Garofalo A,et al.The vascular targeting property of paclitaxel is enhanced by SU6668,a receptor tyrosine kinase inhibitor,causing apoptosis of endothelial cells and inhibition of angiogenesis[J].Clin Cancer Res,2006,12:1839-1849.
  • [19]Chaudhary NI,Roth GJ,Hilberg F,et al.Inhibition of PDGF,VEGF and FGF signalling attenuates fibrosis[J].Eur Respir J,2007,29:976-985.
  • [20]Thomas AL,Morgan B,Horsfield MA,et al.Phase Ⅰ study of the safety,tolerability,pharmacokinetics,and pharmacodynamics of PTK787/ZK222584 administered twice daily in patients with advanced cancer[J].J Clin Oncol,2005,23:4162-4171.
  • [21]Inai T,Mancuso M,Hashizume H,et al.Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations,regression of tumor vessels,and appearance of basement membrane ghosts[J].Am J Pathol,2004,165:35 -52.
  • [22]Rosen LS,Kurzrock R,Mulay M,et al.Safety,pharmacokinetics,and efficacy of AMG706,an oral muhikinase inhibitor,in patients with advanced solid tumors[J].J Clin Oncol,2007,25:2369 -2376.
  • [23]Wong KK.HKI-272 in non-small cell lung cancer[J].Clin Cancer Res,2007,13:4593-4596.
  • [24]Younes MN,Yazici YD,Kim S,et al.Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer[J].Clin Cancer Res,2006,12:3425-3434.
  • [25]Harousseau JL.Farnesyhransferase inhibitors in hematologic malignancies[J].Blood Rev,2007,21:173-182.
  • [26]Reuter CW,Morgan MA,Gruwald V,et al.Targeting vascular endothelial growth factor (VEGF)-receptorsignaling in renal cell carcinoma[J].World J Urol,2007,25:59 -72.
  • [27]Kohno M,Pouyssegur J.Targeting the ERK signaling pathway in cancer therapy[J].Ann Med,2006,38:200-211.
  • [28]Ma FY,Flanc RS,Tesch GH,et al.A pathogenic role for c-Jun amino-terminal kinase signaling in renal fibrosis and tubular cell apoptosis[J].J Am Soc Nephrol,2007,18:472-484.
  • [29]Vivanco I,Sawyers CL.The phosphatidylinositol 3-kinase AKT pathway in human cancer[J].Nat Rev Cancer,2002,2:489-501.
  • [30]Drugs moving into the clinic[EB/OL].2007:1-39.http://www.drugresearcher,com.2007-12-20.
  • [31]de la Pena L,Bnrgan WE,Carter DJ,et al.Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells[J].Mol Cancer Ther,2006,5:1504-1510.
  • [32]MacKenzie AR,yon Mehren M.Mechanisms of mammalian target of rapamyein inhibition in sarcoma:present and future[J].Expert Rev Anticancer Ther,2007,7:1145-1154.
  • [33]Martelli AM,Tazzari PL,Evangelisti C,et al.Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamyein module for acute myelogenous leukemia therapy:from bench to bedside[J].Curr Med Chem,2007,14:2009-2023.
  • [34]Zheng HY,Hu JD,Zheng ZH,et al.Emodin induces leukemic HL-60 cells apoptosis probably by inhibiting Akt signal pathway[J].Acts Pharm Sin (药学学报),2007,42:1142-1146.
  • [35]Boschelli DH,Wu B,Ye F,et al.Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl) amino]-7-furyl-3-quinolinecarbonitriles[J].J Med Chem,2006,49:7868-7876.
  • [36]Gorre ME,Mohammed M,Ellwood K,et al.Clinical resistance to STI571 cancer therapy caused by Bcr-Abl gene mutation or amplification[J].Science,2001,293:876-880.
  • [37]Schenone S,Manetti F,Botta M.Last findings on dual inhibitors of Abl and Sre tyrosine-kinases[J].Mini Rev Med Chem,2007,7:191-201.
  • [38]von Mehren M.Beyond imatinib:second generation cKIT inhibitors for the management of gastrointestinal stromal tumors[J].Clin Colorectal Cancer,2006,6:30-34.
  • [39]Jabbour E,Cortes JE,Giles FJ,et al.Current and emerging treatment options in chronic myeloid leukemia[J].Cancer,2007,109:2171 -2181.
  • [40]O'Sullivan LA,Liongue C,Lewis RS,et al.Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease[J].Mol Immunol,2007,44:2497-2506.
  • [41]Kumar S,Raje N,Hideshima T,et al.Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs[J].Leukemia,2005,19:1253-1261.
  • [42]Barton BE,Karras JG,Murphy TF,et al.Signal transducer and activator of transcription3 (STAT3) activation in prostate cancer:direct STAT3 inhibition induces apoptosis in prostate cancer lines[J].Mol Cancer Ther,2004,3:11-20.
  • [43]Blaskovich MA,Sun J,Cantor A,et al.Discovery of JSI-124 (Cucurbitacin Ⅰ),a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and routine cancer cells in mice[J].Cancer Res,2003,63:1270-1279.
  • [44]Schenone S,Bondavalli F,Botts M.Antiangiogenic agents:an update on small molecule VEGFR inhibitors[J].Curr Med Chem,2007,14:2495 -2516.
  • [45]Duda DG,Jain RK,Willett CG.Antiangiogenics:the potential role of integrating this novel treatment modality with chemoradiation for solid cancers[J].J Clin Oncol,2007,25:4033-4042.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615